Gam1983/iStock via Getty Images
I have previously discussed, in relation to Eli Lilly (LLY), my expectation that the GLP-1 drug class should readily exceed $100 billion in revenues by the end of the decade, due to the impressive data being
LifeMD: A Derivative Beneficiary Of The Demand For Anti-Obesity Pharmaceuticals
Summary
- LifeMD is positioned for rapid growth with the introduction of a weight management program and partnerships with Nutrisystem and Medifast.
- The company has seen an increase in new client signups for its weight loss program, with a goal of reaching 400 per day by the end of 2023.
- LifeMD's revenue is expected to grow significantly, with a consensus forecast of $175 million for 2024, driven by the demand for GLP-1 prescriptions and partnerships in the weight loss industry.
I am an MD by background who runs a healthcare hedge fund. I worked as a sell-side medical analyst for 20 years, covering pharmaceuticals, medical devices, PBMs and drug distributors.
Analyst’s Disclosure:I/we have a beneficial long position in the shares of LFMD either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.
Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.